LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the...
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and...
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody„¢...
Lava Therapeutics said Tuesday that it cut 36% of its staff after the biotech stopped all work on a therapy looking to go after CD1d-expressing hematological tumors.
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody®...
Bispecific developer LAVA Therapeutics is cutting a trial for a candidate targeting hematological malignancies after reviewing the current competitive landscape, choosing instead to double down on its solid tumor program.
¢ LAVA-1207 for the treatment of prostate cancer will continue as the lead program¢ LAVA-051 Phase 1/2a clinical trial will be discontinued¢ Associated cost savings and initiatives are expected to...
Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The...
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.In May 2020, LAVA entered into a research collaboration and license...